Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Quantitative, Multi-institutional Evaluation of MR Thermometry Accuracy for Deep-Pelvic MR-Hyperthermia Systems Operating in Multi-vendor MR-systems Using a New Anthropomorphic Phantom.

Curto S, Aklan B, Mulder T, Mils O, Schmidt M, Lamprecht U, Peller M, Wessalowski R, Lindner LH, Fietkau R, Zips D, Bellizzi GG, van Holthe N, Franckena M, Paulides MM, van Rhoon GC.

Cancers (Basel). 2019 Nov 2;11(11). pii: E1709. doi: 10.3390/cancers11111709.

2.

68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery.

Marzec J, Becker J, Paulsen F, Wegener D, Olthof SC, Pfannenberg C, Schwenck J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC.

Acta Oncol. 2019 Sep 27:1-8. doi: 10.1080/0284186X.2019.1669816. [Epub ahead of print]

PMID:
31559880
3.

Integrative assessment of brain and bone invasion in meningioma patients.

Zwirner K, Paulsen F, Schittenhelm J, Gepfner-Tuma I, Tabatabai G, Behling F, Skardelly M, Bender B, Zips D, Eckert F.

Radiat Oncol. 2019 Jul 29;14(1):132. doi: 10.1186/s13014-019-1341-x.

4.

Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation.

Hauth F, Bizu V, App R, Lautenbacher H, Tenev A, Bitzer M, Malek NP, Zips D, Gani C.

JMIR Mhealth Uhealth. 2019 Jul 24;7(7):e12345. doi: 10.2196/12345.

5.

Watchful Waiting after Radiochemotherapy in Rectal Cancer: When Is It Feasible?

Gani C, Kirschniak A, Zips D.

Visc Med. 2019 Apr;35(2):119-123. doi: 10.1159/000499167. Epub 2019 Mar 27. Review.

6.

[Neuro-Oncology].

Tabatabai G, Tatagiba M, Zips D, Ziemann U.

Nervenarzt. 2019 Jun;90(6):567. doi: 10.1007/s00115-019-0732-4. German. No abstract available.

PMID:
31175406
7.

Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Budach V, Tinhofer I; DKTK-ROG.

Eur J Cancer. 2019 Jul;116:67-76. doi: 10.1016/j.ejca.2019.04.015. Epub 2019 Jun 4.

PMID:
31173964
8.

Organ Preservation in Rectal Cancer: The Patients' Perspective.

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D.

Front Oncol. 2019 May 10;9:318. doi: 10.3389/fonc.2019.00318. eCollection 2019.

9.

Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D.

Zwirner K, Hilke FJ, Demidov G, Socarras Fernandez J, Ossowski S, Gani C, Thorwarth D, Riess O, Zips D, Schroeder C, Welz S.

Strahlenther Onkol. 2019 Sep;195(9):771-779. doi: 10.1007/s00066-019-01478-x. Epub 2019 May 23.

PMID:
31123786
10.

Neutrophil-to-Lymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?

Braun LH, Baumann D, Zwirner K, Eipper E, Hauth F, Peter A, Zips D, Gani C.

Int J Mol Sci. 2019 May 17;20(10). pii: E2448. doi: 10.3390/ijms20102448.

11.

Prospective evaluation of a tumor control probability model based on dynamic 18F-FMISO PET for head-and-neck cancer radiotherapy.

Thorwarth D, Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, la Fougère C, Reischl G, Mauz PS, Paulsen F, Alber ML, Belka C, Zips D.

J Nucl Med. 2019 May 10. pii: jnumed.119.227744. doi: 10.2967/jnumed.119.227744. [Epub ahead of print]

PMID:
31076504
12.

Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.

Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE, Baretton GB, Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M, Troost EGC.

Radiother Oncol. 2019 Jun;135:43-50. doi: 10.1016/j.radonc.2019.02.020. Epub 2019 Mar 9.

PMID:
31015169
13.

Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.

Eckert F, Zwirner K, Boeke S, Thorwarth D, Zips D, Huber SM.

Front Immunol. 2019 Mar 12;10:407. doi: 10.3389/fimmu.2019.00407. eCollection 2019. Review.

14.

Comparison of subjective evaluation versus objective algorithm in the interpretation of follow-up FDG-PET/CT scans after radiochemotherapy in head and neck cancer patients.

Kohler A, Löck S, Appold S, Bandurska-Luque A, Hoberück S, Schreiber A, Kotzerke J, Zips D, Zöphel K.

Nuklearmedizin. 2019 Mar;58(2):93-100. doi: 10.1055/a-0859-6518. Epub 2019 Mar 27.

PMID:
30917398
15.

[Lateral pelvic lymph nodes in locally advanced rectal carcinoma-an underestimated site of recurrence?]

Gani C, Kirschniak A, Zips D.

Strahlenther Onkol. 2019 Jun;195(6):576-578. doi: 10.1007/s00066-019-01447-4. German. No abstract available.

PMID:
30859255
16.

Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery.

Schwenck J, Olthof SC, Pfannenberg C, Reischl G, Wegener D, Marzec J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC.

J Nucl Med. 2019 Oct;60(10):1359-1365. doi: 10.2967/jnumed.118.224543. Epub 2019 Mar 8.

PMID:
30850491
17.

Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Perrin R, Appold S, Krause M, Steinbach J, Kotzerke J, Hofheinz F, Zips D, Baumann M, Troost EGC.

Clin Transl Radiat Oncol. 2019 Feb 15;15:108-112. doi: 10.1016/j.ctro.2019.02.002. eCollection 2019 Feb.

18.

Radiation Pneumonitis after Intensity-Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a Systematic Review.

Tonison JJ, Fischer SG, Viehrig M, Welz S, Boeke S, Zwirner K, Klumpp B, Braun LH, Zips D, Gani C.

Sci Rep. 2019 Feb 19;9(1):2255. doi: 10.1038/s41598-018-38414-5.

19.

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F.

Eur J Cancer. 2019 Mar;110:11-20. doi: 10.1016/j.ejca.2018.12.023. Epub 2019 Feb 7.

20.

Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells.

Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schüler U, Zips D, Eckert F, Huber SM.

Cancers (Basel). 2019 Jan 18;11(1). pii: E110. doi: 10.3390/cancers11010110.

21.

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer.

Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin EC, Schwab M, Zips D, Huber SM.

Front Immunol. 2018 Dec 21;9:3018. doi: 10.3389/fimmu.2018.03018. eCollection 2018. Review.

22.

Hyperthermic chest wall re-irradiation in recurrent breast cancer: a prospective observational study.

De-Colle C, Weidner N, Heinrich V, Brucker S, Hahn M, MacMillan K, Lamprecht U, Gaupp S, Voigt O, Zips D.

Strahlenther Onkol. 2019 Apr;195(4):318-326. doi: 10.1007/s00066-018-1414-z. Epub 2019 Jan 3.

PMID:
30607453
23.

Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.

Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A.

Immunotherapy. 2019 Mar;11(4):297-309. doi: 10.2217/imt-2018-0149. Epub 2019 Jan 4.

PMID:
30606066
24.

Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Wegener D, Lang P, Paulsen F, Weidner N, Zips D, Ebinger M, Holzer U, Döring M, Basu O, Gruhn B, Wittig A, Teltschik HM, Handgretinger R, Heinzelmann F.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):137-143. doi: 10.1016/j.ijrobp.2018.12.031. Epub 2018 Dec 26.

PMID:
30593907
25.

Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy.

Li R, Helbig L, Fu J, Bian X, Herrmann J, Baumann M, Stewart AF, Müller R, Li A, Zips D, Zhang Y.

Res Microbiol. 2019 Mar;170(2):74-79. doi: 10.1016/j.resmic.2018.11.001. Epub 2018 Nov 14.

PMID:
30447257
26.

Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Eckert F, Schaedle P, Zips D, Schmid-Horch B, Rammensee HG, Gani C, Gouttefangeas C.

Oncoimmunology. 2018 Aug 27;7(11):e1496881. doi: 10.1080/2162402X.2018.1496881. eCollection 2018.

27.

Comparison of treatment plans for a high-field MRI-linac and a conventional linac for esophageal cancer.

Nachbar M, Mönnich D, Kalwa P, Zips D, Thorwarth D, Gani C.

Strahlenther Onkol. 2019 Apr;195(4):327-334. doi: 10.1007/s00066-018-1386-z. Epub 2018 Oct 25.

PMID:
30361744
28.

Potentials and challenges of diffusion-weighted magnetic resonance imaging in radiotherapy.

Leibfarth S, Winter RM, Lyng H, Zips D, Thorwarth D.

Clin Transl Radiat Oncol. 2018 Sep 20;13:29-37. doi: 10.1016/j.ctro.2018.09.002. eCollection 2018 Nov. Review.

29.

FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Abolmaali N, Seidlitz A, Appold S, Krause M, Steinbach J, Kotzerke J, Zips D, Baumann M, Troost EGC.

Radiother Oncol. 2019 Jan;130:97-103. doi: 10.1016/j.radonc.2018.09.008. Epub 2018 Oct 4.

PMID:
30293643
30.

Precision of T2 TSE MRI-CT-image fusions based on gold fiducials and repetitive T2 TSE MRI-MRI-fusions for adaptive IGRT of prostate cancer by using phantom and patient data.

Wegener D, Zips D, Thorwarth D, Weiß J, Othman AE, Grosse U, Notohamiprodjo M, Nikolaou K, Müller AC.

Acta Oncol. 2019 Jan;58(1):88-94. doi: 10.1080/0284186X.2018.1518594. Epub 2018 Sep 28.

PMID:
30264629
31.

A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger H, Ganswindt U, Henke M, Belka C.

Clin Cancer Res. 2019 Mar 1;25(5):1505-1516. doi: 10.1158/1078-0432.CCR-18-0776. Epub 2018 Aug 31.

PMID:
30171046
32.

Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase.

Tiwari A, Rebholz S, Maier E, Dehghan Harati M, Zips D, Sers C, Rodemann HP, Toulany M.

Int J Mol Sci. 2018 Aug 18;19(8). pii: E2441. doi: 10.3390/ijms19082441.

33.

Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study.

Braun LH, Braun K, Frey B, Wolpert SM, Löwenheim H, Zips D, Welz S.

Strahlenther Onkol. 2018 Dec;194(12):1124-1131. doi: 10.1007/s00066-018-1344-9. Epub 2018 Aug 14.

PMID:
30109361
34.

Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy.

Zwirner K, Hilke FJ, Demidov G, Ossowski S, Gani C, Rieß O, Zips D, Welz S, Schroeder C.

Radiother Oncol. 2018 Dec;129(3):575-581. doi: 10.1016/j.radonc.2018.07.016. Epub 2018 Aug 7.

PMID:
30097252
35.

CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer.

Leger S, Zwanenburg A, Pilz K, Zschaeck S, Zöphel K, Kotzerke J, Schreiber A, Zips D, Krause M, Baumann M, Troost EGC, Richter C, Löck S.

Radiother Oncol. 2019 Jan;130:10-17. doi: 10.1016/j.radonc.2018.07.020. Epub 2018 Aug 4.

PMID:
30087056
36.

Prospective data registration and clinical trials for particle therapy in Europe.

Langendijk JA, Orecchia R, Haustermans K, Zips D, Balosso J, Lacombe D, Lievens Y, Weber DC, Grau C, Troost EGC.

Radiother Oncol. 2018 Jul;128(1):9-13. doi: 10.1016/j.radonc.2018.06.001. Epub 2018 Jul 7. Review.

PMID:
30056852
37.

Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer.

Gani C, Grosse U, Clasen S, Kirschniak A, Goetz M, Rödel C, Zips D.

Strahlenther Onkol. 2018 Nov;194(11):985-990. doi: 10.1007/s00066-018-1327-x. Epub 2018 Jul 9.

PMID:
29987338
38.

MATLAB®-based fitting method to evaluate survival fractions after multimodal treatment.

Marzec J, Marzec L, Martus P, Zips D, Müller AC.

Clin Transl Radiat Oncol. 2018 Mar 29;10:36-41. doi: 10.1016/j.ctro.2018.03.003. eCollection 2018 Mar.

39.

[Locoregional hyperthermia improves disease-specific overall survival in combination with neoadjuvant chemotherapy in high-risk soft tissue sarcomas].

Eckert F, Zips D.

Strahlenther Onkol. 2018 Aug;194(8):787-789. doi: 10.1007/s00066-018-1322-2. German. No abstract available.

PMID:
29882096
40.

Automatic replanning of VMAT plans for different treatment machines: A template-based approach using constrained optimization.

Künzel LA, Dohm OS, Alber M, Zips D, Thorwarth D.

Strahlenther Onkol. 2018 Oct;194(10):921-928. doi: 10.1007/s00066-018-1319-x. Epub 2018 May 30.

PMID:
29846751
41.

Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients.

Winter RM, Leibfarth S, Schmidt H, Zwirner K, Mönnich D, Welz S, Schwenzer NF, la Fougère C, Nikolaou K, Gatidis S, Zips D, Thorwarth D.

Radiother Oncol. 2018 Sep;128(3):485-491. doi: 10.1016/j.radonc.2018.04.018. Epub 2018 May 7.

42.

Organ preservation in rectal cancer - Challenges and future strategies.

Gani C, Bonomo P, Zwirner K, Schroeder C, Menegakis A, Rödel C, Zips D.

Clin Transl Radiat Oncol. 2017 Mar 23;3:9-15. doi: 10.1016/j.ctro.2017.02.002. eCollection 2017 Apr. Review.

43.

Rendezvous endoscopic recanalization for complete esophageal obstruction.

Fusco S, Kratt T, Gani C, Stueker D, Zips D, Malek NP, Goetz M.

Surg Endosc. 2018 Oct;32(10):4256-4262. doi: 10.1007/s00464-018-6174-4. Epub 2018 Mar 30.

PMID:
29602985
44.

Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report.

Braun LH, Welz S, Viehrig M, Heinzelmann F, Zips D, Gani C.

Clin Transl Radiat Oncol. 2017 Dec 8;9:1-4. doi: 10.1016/j.ctro.2017.12.001. eCollection 2018 Feb.

45.

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy.

Bütof R, Gumina C, Valentini C, Sommerer A, Appold S, Zips D, Löck S, Baumann M, Troost EGC.

Clin Transl Radiat Oncol. 2017 Nov 6;7:36-42. doi: 10.1016/j.ctro.2017.09.010. eCollection 2017 Dec.

46.

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy.

De-Colle C, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Jawad JA, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Bayer C, Belka C, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D, Menegakis A.

Clin Transl Radiat Oncol. 2017 Jul 14;5:28-36. doi: 10.1016/j.ctro.2017.06.004. eCollection 2017 Aug.

47.

Cell-line dependent effects of hypoxia prior to irradiation in squamous cell carcinoma lines.

Hauth F, Toulany M, Zips D, Menegakis A.

Clin Transl Radiat Oncol. 2017 Jul 4;5:12-19. doi: 10.1016/j.ctro.2017.06.001. eCollection 2017 Aug.

48.

Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup.

Zwirner K, Thorwarth D, Winter RM, Welz S, Weiss J, Schwenzer NF, Schmidt H, la Fougère C, Nikolaou K, Zips D, Gatidis S.

Strahlenther Onkol. 2018 Aug;194(8):719-726. doi: 10.1007/s00066-018-1292-4. Epub 2018 Mar 21.

PMID:
29564483
49.

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Sedlmayer F, Wenz F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).

Strahlenther Onkol. 2018 Jul;194(7):619-626. doi: 10.1007/s00066-018-1269-3. Epub 2018 Jan 30. Review.

PMID:
29383406
50.

Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.

Basler L, Kowalczyk A, Heidenreich R, Fotin-Mleczek M, Tsitsekidis S, Zips D, Eckert F, Huber SM.

Cancer Immunol Immunother. 2018 Apr;67(4):653-662. doi: 10.1007/s00262-018-2117-0. Epub 2018 Jan 16.

PMID:
29335856

Supplemental Content

Support Center